If the vertical integration efforts continue, Nevro makes further successful marketing efforts, and internationalization works out, FCF will likely trend up.

Source: https://seekingalpha.com/article/4602274-nevro-potentially-better-than-traditional-scs-treatment-for-pain-and-undervalued?source=feed_all_articles

Mackenzie Financial Corp raised its position in Nevro by 33.3% in the 2nd quarter.

Source: https://www.etfdailynews.com/2023/08/07/equities-analysts-set-expectations-for-nevro-corp-s-q3-2023-earnings-nysenvro/

Wells Fargo & Company lowered their target price on Nevro from $27.00 to $23.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 2nd.

Source: https://www.americanbankingnews.com/2023/11/04/nevro-nysenvro-pt-lowered-to-15-00-at-piper-sandler.html